Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

2 evidence topics · 2 sources

Pregnancy and breastfeeding: IMPALA-2 exclusions

“Pregnant and breastfeeding women will not be included” (opens the source at this quote in a new tab)

Adolescent case report

“We here describe a unique case of a 14-year-old patient who was successfully treated with WLL and subsequent inhalations with molgramostim” (opens the source at this quote in a new tab)

Renal impairment

No evidence found.

Hepatic impairment

No evidence found.